<DOC>
	<DOCNO>NCT00002995</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . It yet know whether chemotherapy effective without radiation therapy treat patient rhabdomyosarcoma . PURPOSE : Phase III trial compare effectiveness chemotherapy without radiation therapy treat patient newly-diagnosed rhabdomyosarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Radiation Therapy Treating Patients With Newly Diagnosed Rhabdomyosarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine failure-free survival ( FFS ) rate patient newly diagnose low-risk rhabdomyosarcoma embryonal botryoid subtype meeting criterion group I treatment dactinomycin vincristine without radiotherapy . - Determine FFS rate patient meet criterion group II treatment dactinomycin , vincristine , cyclophosphamide without radiotherapy . - Determine FFS rate patient ectomesenchymomas contain rhabdomyosarcomatous element ( embryonal histiotype ) receive one treatment . - Determine new molecular marker specific embryonal botryoid tumor histology diagnostic prognostic significance patient treat regimen . OUTLINE : Patients assign 1 2 group , depend histology site disease . - Group I ( favorable tumor site , negative lymph node , stage 1 , clinical group I , IIA , III ( orbit ) , node negative [ N0 ] OR unfavorable tumor site , negative unknown lymph node , stage 2 , clinical group I ) : Patients receive vincristine IV 1 minute weekly 8 week dactinomycin IV 1 minute every 3 week 4 dos . Treatment repeat every 12 week 4 course . Radiotherapy administer patient clinical group II III disease week 3-8 . - Group II ( favorable tumor site , positive lymph node , stage 1 , clinical group III ( orbit ) , node positive [ N1 ] OR favorable tumor site except orbit , lymph node , stage 1 , clinical group III OR unfavorable tumor site , stage 2 , clinical group II OR unfavorable tumor site , stage 3 , clinical group I II ) : Patients receive vincristine dactinomycin group I . Patients also receive cyclophosphamide IV 30-60 minute filgrastim ( G-CSF ) sargramostim ( GM-CSF ) subcutaneously daily begin 24 hour completion chemotherapy continue 10 day blood count recover . Radiotherapy administer week 3-8 , 12-17 , 28-33 , clinically indicate group I . Patients follow every 3-4 month 3 year ( 4 year diagnosis ) , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 254 patient group I accrue study within 6 year . Approximately 12 patient per year accrue group II .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm embryonal ( EMB ) rhabdomyosarcoma ( RMS ) botryoid spindle cell variant EMB RMS embryonal ectomesenchymoma meeting 1 follow criterion : Stage 1 , clinical group IV : Tumor favorable site ( orbit , head neck [ exclude parameningeal ] , genitourinary [ bladder/prostate ] , biliary tract ) metastatic disease Stage 2 3 , clinical group I II : Tumor unfavorable site ( bladder/prostate , extremity , cranial parameningeal , trunk , retroperitoneum , pelvis , perineal/perianal , intrathoracic , gastrointestinal , liver ) , gross residual disease initial surgery , metastatic disease Must ipsilateral lymph node dissection age 10 primary paratesticular cancer OR age 10 clinically positive regional lymph node Low risk recurrence Previously untreated disease No alveolar RMS undifferentiated sarcoma No intermediaterisk disease No metastatic disease diagnosis PATIENT CHARACTERISTICS : Age : Under 50 Performance status : Not specify Hematopoietic : Not specify Hepatic : Bilirubin elevation secondary biliary hepatic primary allow Renal : Creatinine elevation secondary tumor obstruction allow Other : No uncontrolled infection Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>embryonal childhood rhabdomyosarcoma</keyword>
	<keyword>embryonal-botryoid childhood rhabdomyosarcoma</keyword>
	<keyword>previously untreated childhood rhabdomyosarcoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>adult malignant mesenchymoma</keyword>
	<keyword>childhood malignant mesenchymoma</keyword>
	<keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
	<keyword>stage II adult soft tissue sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>stage I adult soft tissue sarcoma</keyword>
</DOC>